IL6R and prostate neoplasm: We previously examined a first-generation IL-27 targeted at the C-terminus with a short ‘peptide L’ (pepL, LSLITRL), which binds the interleukin 6 receptor α (IL-6Rα) that is upregulated in tumor cells [7] in order to reduce prostate tumor growth (IL-27pepL or 27pepL) [4,8,9].